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Abstract
Background—A previous case report of West Nile virus (WNV) illness during pregnancy 
suggested that WNV could be a cause of congenital defects. We performed a prospective, 
longitudinal cohort study of pregnant women with WNV illness to increase our knowledge of the 
effects of WNV illness during pregnancy.
Methods—Participants were enrolled in 2005 to 2008 from pregnant women with serologically 
confirmed WNV illness reported to the Centers for Disease Control and Prevention. Comparison 
was made to WNV-uninfected women, matched on maternal age and enrollment month. Pregnancy 
and newborn data were collected; cord blood WNV serology was obtained. Pediatric exams and 
the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III) were performed.
Results—Twenty-eight WNV-infected mothers and 25 WNV-uninfected mothers participated. 
Maternal demographics were similar except for a higher rate of planned pregnancies, education, 
and household income in the WNV-uninfected mothers. There were no differences in pregnancy 
and delivery characteristics except that infected mothers had a higher incidence of febrile illnesses 
and used more medications. Birth weight, length, head circumference, and rate of congenital 
malformations were similar in babies born to WNV-infected and -uninfected mothers. Follow-up 
physical exams were generally normal. The Bayley-III assessments, available for 17 children born 
to mothers with WNV illness, showed performance at or above age level across domains.
Conclusion—The risk for adverse pregnancy and newborn outcomes in women experiencing 
WNV illness in pregnancy appears to be low, but future studies with larger numbers are needed to 
rule out a small risk.
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Introduction
In 2002, 3 years after West Nile virus (WNV) was first detected in the Western hemisphere 
(Nash et al., 1999), the first case of maternal infection with vertical transmission during 
human pregnancy was reported (CDC MMWR, 2002a). The mother developed WNV 
encephalitis at 27 weeks of gestation, recovered from her acute illness, but subsequently 
delivered a full-term infant with chorioretinitis, cystic destruction of cerebral tissue, and 
laboratory evidence of WNV infection.
The finding of neurologic abnormalities in the newborn of the infected mother reported in 
2002 led to concern that WNV infection might be teratogenic, particularly to the central 
nervous system. Subsequently, O’Leary et al. (2006) described the outcomes of 72 newborns 
of mothers infected by WNV who were reported to the Centers for Disease Control and 
Prevention (CDC) between 2003 and 2004. Three infants had WNV infection that could 
have been congenitally acquired but postnatal infection through mosquito bite or breast milk 
could not be ruled out. One of these three infants had lissencephaly, but this was not thought 
to be attributable to the WNV infection based on the timing of the mother’s infection.
To increase the knowledge regarding the effects of WNV illness during pregnancy on infant 
outcomes, we performed a prospective, longitudinal, cohort study of pregnant women with 
WNV illness. We specifically assessed pregnancy and newborn outcomes, particularly to 
determine the risk of congenital malformations (primary outcome). Given the report of 
chorioretinitis and cystic destruction of cerebral tissue in an infected newborn, we 
hypothesized that we would see a higher rate of congenital malformations, particularly of the 
central nervous system, in infants born to WNV-infected mothers.
Material and Methods
This study enrolled pregnant women with serologically confirmed WNV illness reported to 
the CDC from 2005 through 2008. When WNV illness in a pregnant woman was reported to 
the CDC, the mother was invited to participate in the study.
We also prospectively recruited uninfected pregnant women from hospitals where study 
participants with WNV illness delivered, and from local area hospitals, such as Tulane 
Hospital and Clinic and Medical Center of Louisiana, New Orleans. The study was approved 
by the Tulane University Biomedical Institutional Review Board.
Women with WNV infection during pregnancy who were invited to participate had 
laboratory criteria for diagnosis included the following: (1) fourfold or greater change in 
virus-specific serum antibody titer; or (2) isolation of virus from tissue, blood, cerebrospinal 
fluid, or other body fluid; or (3) virus-specific immunoglobulin M (IgM) antibodies 
demonstrated in cerebrospinal fluid by antibody-capture enzyme-linked immunosorbent 
assay (ELISA), or (4) virus-specific IgM antibodies demonstrated in serum by antibody-
capture ELISA and confirmed by demonstration of virus-specific serum immunoglobulin G 
(IgG) antibodies in the same or a later specimen by another serologic assay (e.g., 
neutralization or hemagglutination inhibition).
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WNV-uninfected mothers were pregnant women who had no symptoms consistent with 
encephalitis or meningitis at any time during pregnancy, no other exposure that was believed 
to be teratogenic, and no preexisting diabetes. Cord blood from potential uninfected 
participants was tested for WNV IgG to confirm uninfected status; participants whose 
specimens indicated past WNV infection were removed from the study. Uninfected 
participants were matched to the infected participants by month of gestation and age group 
(less than 25, 25–35, and greater than 35 years of age) at enrollment.
LABORATORY TESTING
Cord blood from infants born to WNV-infected mothers were tested at Tulane University 
School of Public Health and Tropical Medicine for the presence of WNV IgM antibodies 
using the West Nile Virus IgM Capture DxSelectTM ELISA kit (Focus Diagnostics, Cypress, 
CA) according to the manufacturer’s instructions. Cord blood of infants born to WNV-
uninfected mothers was tested for WNV specific IgG. Confirmation of WNV diagnosis was 
performed with anti-WNV neutralizing antibodies by using a Plaque Reduction 
Neutralization Test (Lieberman et al., 2009).
OUTCOME ASSESSMENT
Information on demographics, socioeconomic status, and family history of birth defects was 
obtained for infected and noninfected mothers by a self-administered questionnaire at the 
time of enrollment. The mother’s physician completed a questionnaire regarding the 
maternal prenatal course and intrapartum complications. Supplemental information was 
obtained from review of the medical record pertaining to pregnancy and delivery.
Infant outcomes were obtained from the medical record and the infant’s healthcare 
provider’s completed questionnaire regarding examination at birth and follow up visits. 
Study physicians did not systematically examine study newborns. A newborn was 
designated small-for-gestational-age if birth weight was less than the 10th percentile for 
gestational age at birth and large-for-gestational-age if the birth weight for gestational age 
was greater than the 90th percentile using US data from intrauterine growth curves of Olsen 
et al. (2010). Pediatricians were recommended to follow the interim guidelines for 
evaluation of babies born to mothers with WNV illness in pregnancy (MMWR, 2004). 
Babies were examined by their pediatrician at birth and at 6 months intervals until 2 years of 
age. Infants had hearing and vision screening; full ophthalmologic examination was 
provided to the pediatrician free of charge.
Birth defects were defined according to the CDC’s Metropolitan Atlanta Congenital Defects 
Program guidelines (CDC, 2004). Birth defects were classified as major or minor. Major 
anomalies were defined as those that create significant medical problems or require specific 
surgical or medical management. Minor anomalies were features that may vary from those 
that are commonly seen in the normal population but alone do not cause increased 
morbidity.
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DEVELOPMENTAL TESTING
The Bayley Scales of Infant and Toddler Development –Third Edition (Bayley-III) were 
administered to children at approximately 24 months of age by local participating 
psychologists, using standardized assessment procedures (Bayley, 2006). The Bayley-III 
provides standardized measures of child development in five domains: Cognitive (problem-
solving), Language (receptive and expressive skills), Motor (fine- and gross-motor skills), 
Social-Emotional (social behavior and self-regulation), and Adaptive Behavior (for example, 
communication, self-care, and pre-academic skills). The Cognitive, Language, and Motor 
domains are assessed through direct testing with the child; the Social-Emotional and 
Adaptive Behavior domains are assessed through interviews with the parent. The 
standardization sample of the Bayley-III provides the reference mean for the domain 
composite scores (Mean = 100, standard deviation [SD] = 15).
Statistical analysis was performed by the two-sided Student’s t test for continuous data, chi 
square and Fisher’s Exact test for categorical data and the Mann-Whitney U test for 
nonparametric data. An alpha error probability of less than 0.05 was considered statistically 
significant.
Results
Of the 49 cases of WNV illness in pregnancy reported to the CDC from 2005 to 2008 
(Nicole Lindsey, personal communication), 28 mothers agreed to participate in this study; 
data are available for 26 WNV-uninfected women who were matched for age category, and 
trimester of pregnancy at enrollment. One mother from Louisiana selected for the uninfected 
group was excluded from the study because of evidence of prior WNV infection based on 
the presence of WNV IgG in cord blood.
At initial enrollment, the most common symptom of women in the WNV illness group was 
fever, reported in 20 of 28; a diagnosis of meningitis or encephalitis was made in 11 women, 
3 of whom did not report fever. Other commonly reported maternal symptoms were rash, 
headache, nausea, vomiting, fatigue, poor concentration, and muscle weakness. Onset of 
WNV illness occurred in 4, 11, and 13 women in the first, second, and third trimesters, 
respectively.
Self-reported maternal characteristics in the WNV-infected and -uninfected groups were 
generally similar except for a higher number of planned pregnancies (p = 0.002), level of 
education (p = 0.005), and household income (p = 0.002) in the uninfected group (Table 1). 
There were no significant differences between the groups in rates of family history of birth 
defects.
Pregnancy characteristics as well as pre-existing pregnancy complications were generally 
similar between groups (Table 2). One woman in the WNV illness group had epilepsy before 
pregnancy but was not on anti-seizure medication. No women in the uninfected group 
reported a pre-existing medical condition. The incidence of prior spontaneous abortion, 
preterm birth, stillbirth, fetal growth restriction, and preeclampsia were similar between the 
groups. In the WNV illness group, one woman had a previous child with Down syndrome. 
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There were no differences between the WNV-infected and -uninfected groups in frequency 
of prenatal care or folic acid supplementation.
MATERNAL OUTCOMES
Women in the WNV illness group had more episodes of febrile illness (p < 0.001) and used 
more medications during the pregnancy (p = 0.001; Table 2). No woman in either group 
developed gestational diabetes, oligohydramnios, polyhydramnios, or preterm premature 
rupture of membranes. The frequencies of other pregnancy complications such as 
hypertension, vaginal bleeding after 20 weeks, placental abruption, and placenta previa were 
not statistically different between the groups. The rates of intrapartum complications and the 
cesarean delivery rate were similar among both groups. One woman in the WNV illness 
group underwent an emergent cesarean section at 30 weeks of gestation because of placental 
abruption that occurred 3 weeks after the onset of WNV symptoms. A second WNV-infected 
mother was diagnosed with a placental abruption at 37 weeks of gestation, 19 weeks after 
onset of WNV symptoms. The diagnosis of placental abruption was made on the basis of 
vaginal bleeding. Other than the bleeding, the mother had an uneventful labor and delivered 
a healthy newborn by the vaginal route.
NEWBORN OUTCOMES
None of the infants born to WNV-infected mothers were born with evidence of clinical 
infection, and none were noted to have neurologic deficits at birth. No infants born to WNV-
infected mothers tested positive for WNV IgM (Table 3). There were no stillbirths. All 
newborns delivered at or near term except one aforementioned infant born to a WNV-
infected mother at 30 weeks gestation because of placental abruption. The newborn was 
born with a birth weight average for gestational age and died shortly after emergency 
cesarean delivery. Serologic testing of cord blood was negative for WNV IgM. Placental 
pathology was normal; autopsy was not performed, but there were no gross structural 
abnormalities noted. Neonatal death was attributed to placental abruption.
Mean birth weight, birth length, head circumference, and median APGAR scores at 1 and 5 
min were similar in the maternal WNV-infected and -uninfected groups. Based on review of 
medical records, no baby was reported to have dysmorphic features. Hearing screen was 
normal at birth or at subsequent physical examinations for 26 of 27 newborns of mothers 
with WNV illness (excluding neonatal death) and 23 of 25 newborns in the WNV-uninfected 
group. Hearing testing data were not available for one child in the WNV group and two in 
the WNV-uninfected group.
NEWBORN FOLLOW-UP
Information from pediatric postnatal examinations was available for 22 babies of mothers 
with WNV illness and 8 babies born to uninfected mothers at 2 months of age; 19 and 11 
children, respectively, at 6 months of age; 19 and 9, respectively, at 12 months of age. 
Pediatric examinations were available for 8 children of WNV-infected mothers at 18 and 24 
months, but no children of WNV-uninfected mothers.
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The frequency of congenital anomalies was not different between the maternal WNV-
infected and -uninfected groups. One child born to a mother in the WNV-infected group had 
a major birth defect, pyloric stenosis, muscular hypertrophy of the pylorus causing 
obstruction to the duodenum. The mother of this child also had pyloric stenosis requiring 
surgical repair. No children in the WNV-uninfected group had major birth defects. One child 
in the WNV-infected group had a minor birth defect, an umbilical hernia diagnosed at 12 
months of age. One child in the WNV-uninfected group had minor birth defect, a patent 
foramen ovale (failure of timely postnatal closure of the foramen ovale), that resolved during 
the first year of life. No other congenital malformations were found. Vision screening was 
normal in the WNV-illness and WNV-uninfected groups. Detailed ophthalmologic 
examination with retinal exam was performed on 22 children in the WNV-illness group and 
1 child in the control group (because of mild ptosis that resolved). No visual or retinal 
abnormalities were noted.
DEVELOPMENTAL OUTCOMES
Seventeen children in the maternal WNV illness group completed the Bayley-III. Mean age 
at testing was 28.6 months (range, 18–35 months). Most of the children performed at or 
above age level across domains (Table 4). Two children showed mild delays: one on the 
Cognitive domain (standard score [SS] = 80) and one on the Language (SS = 79), Social-
Emotional (SS = 60), and Adaptive (SS = 80) domains. The Bayley-III was not performed 
for children in the uninfected group; however, development screenings were performed 
during their physical examinations and no deficiencies were noted except for one child with 
mild fine-motor delay at 12 months of age.
Discussion
In our prospective cohort study, none of the children of mothers with WNV illness during 
the pregnancy were born with evidence of WNV infection, either clinically or by detection 
of WNV-specific IgM antibody in their cord blood. Thus, we had no evidence of 
transplacental transmission of WNV to any newborns among 28 mothers in our study with 
WNV during pregnancy. Furthermore, we did not find a greater rate of congenital 
malformations or developmental delay in children born of mothers who had WNV illness in 
pregnancy, compared with infants born to WNV-uninfected mothers. The congenital 
malformations seen in our study were not of the central nervous system, and were within the 
range of frequency of anomalies seen in the general population (Frias and Carey, 1996; 
CDC, 2004; Correa et al., 2007).
WNV is a neurotropic virus transmitted primarily through infected mosquitoes. Only 
approximately 20 to 25% of infected individuals become symptomatic (Petersen et al., 
2013). Of symptomatic individuals, most develop nonneuroinvasive disease, manifested by 
fever, headache, fatigue, malaise, poor concentration, muscle pain, and weakness, which is 
eventually self-limiting (Hayes et al., 2005). The remainder develops neuroinvasive disease, 
including encephalitis, meningitis, or acute flaccid paralysis. In children, WNV illness is 
more likely to manifest as meningitis compared with older adults (Lindsey et al., 2009).
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Until recently, little was known regarding WNV infection in pregnancy. In a mouse model, 
WNV was shown to infect placenta and possibly mouse embryos (Julander et al., 2006). The 
2002 case report (CDC MMRW, 2002a; Alpert et al., 2003) demonstrated that maternal 
infection with WNV in the late second trimester of pregnancy could be transplacentally 
transmitted to the fetus and could possibly be teratogenic to the central nervous system. 
Subsequently, several pregnant women with WNV illness were reported without evidence of 
transplacental transmission (Chapa et al., 2003; Bruno et al., 2004; Skupski et al., 2006). 
One pregnant woman with WNV illness was reported with probable WNV transmission to 
her child through breast milk (CDC MMWR, 2002b), but this was likely a rare event 
(Hinckely et al., 2007). In the retrospective assessment of 77 pregnant women with WNV 
illness reported to the CDC during 2003 to 2004, four mothers had spontaneous abortions, 
two had elective terminations of pregnancy, and the remaining 71 mothers delivered 72 live 
infants. Of the 66 newborns for whom information was available, 7 had a major birth defect 
(aortic coarctation, cleft palate, Down syndrome, lissencephaly, microcephaly, polydactyly) 
(O’Leary et al., 2006). However, there was no evidence of transplacental transmission, with 
cord blood serologic testing negative for WNV-specific IgM.
In our study, pregnancy complications were not higher in the mothers who had WNV illness 
in pregnancy. Similar rates of complications were seen in the babies born to mothers with 
and without WNV illness. Of note, two mothers in the WNV illness group had a placental 
abruption and none in the WNV-uninfected group. One mother, diagnosed with WNV 
encephalitis at 21weeks of gestation, presented at 38 weeks of gestation with bleeding and 
was diagnosed with a placental abruption, but labor and delivery were unremarkable. The 
other had an acute placental abruption diagnosed 3 weeks after onset of WNV meningitis; 
emergency cesarean delivery at 30 weeks was performed, followed by neonatal death. 
Because the newborn’s cord blood was negative for WNV-specific IgM and there were no 
signs of chorioamnionitis or placental pathology, it is unlikely that WNV infection was 
causative.
Developmental testing in the children born of mothers with WNV illness in pregnancy was 
generally normal; global developmental delays were not noted. This finding is in 
concordance with a retrospective study of developmental outcomes in children born to 
mothers with West Nile illness during pregnancy (Sirois et al., 2014). These data represent 
early childhood developmental assessments; no information is available regarding 
development in later childhood.
One mother initially selected for the WNV-uninfected group (from Louisiana) was excluded 
from our study because cord blood was positive for WNV IgG, evidence of previous WNV 
infection. Paisley et al. (2006) showed that after a community-wide epidemic in a Northern 
Colorado community, 569 asymptomatic women who presented to labor and delivery had 
cord blood assessment of WNV-specific antibodies; 4% (95% confidence interval, 2.4–
5.7%) had WNV-specific IgG antibodies but not WNV-IgM.
Our study has several strengths. The prospective, longitudinal nature of the study design 
allowed us to follow women with documented WNV illness during pregnancy. Additionally, 
all newborns born to WNV-infected mothers had cord blood testing for congenital infection 
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using WNV-specific IgM. The study also has several limitations. Our original sample size 
calculation was based on the assumption of a 10% adverse pregnancy outcomes (including 
malformations) in the uninfected women; we would require 51 exposed women and 102 
unexposed women to detect a relative risk of 3.00 at 80% power and α = 0.05. However, we 
were only able to enroll 49 women infected WNV reported to the CDC during our study 
period. Of 49 women with WNV illness, only 28 women agreed to participate in this study. 
Therefore, our study has limited statistical power to detect possible differences in rates of 
adverse pregnancy outcomes. Furthermore, it is possible that more second and third 
trimester WNV illness mothers were enrolled if mothers with first trimester WNV illness 
experienced a spontaneous pregnancy loss. Also, the WNV-uninfected mothers in our study 
had more planned pregnancies, a higher level of education, and higher household income, 
suggesting the possibility of selection bias in the samples.
While various investigators may use different definitions of anomalies, we ultimately 
compared the two groups, and our designation of anomalies was similar for each group. We 
chose to list what was seen and be more inclusive. For example, we could have removed the 
pyloric stenosis, the child’s mother had pyloric stenosis (multifactorial, polygenic 
inheritance) by attributing the malformation to genetic risk alone and not teratogenicity. We 
could have also removed Down syndrome as it is well known that it does not develop as a 
result of teratogenicity. However, the authors believed it important to be complete in 
reporting.
In summary, based on our study, the risk of congenital infection, congenital malformations, 
and developmental delay among infants born to women infected with WNV illness during 
pregnancy does not appear to be elevated, but future studies with larger numbers are needed 
to rule out a small risk.
Pregnant women should avoid mosquito-infested areas, especially at times of high mosquito 
infestation (summer and early fall) and particularly in the early morning and late evening. 
Pregnant women should also wear protective clothing and use insect repellent for prevention 
(CDC, 2015).
WNV should be considered as a cause of illness in mothers with meningitis or related 
symptoms throughout the year because seasonal epidemics are difficult to predict (Jamieson 
et al., 2006; Lindsey et al., 2010). In suspected cases of WNV illness in pregnancy, 
confirmation of maternal infection can be performed with WNV serology. If maternal West 
Nile virus illness is diagnosed, a detailed ultrasound examination of the fetus to evaluate for 
structural abnormalities should be considered no sooner than 2 to 4 weeks after onset of 
illness in the mother. Amniotic fluid, chorionic villi, or fetal serum can be tested for 
evidence of West Nile virus infection. However, the sensitivity, specificity, and predictive 
value of tests that might be used to evaluate fetal infection are not known.
It is not clear if these findings for West Nile Virus have implications for the emerging Zika 
virus outbreak in the Americas. Although West Nile and Zika virus are closely related 
flaviruses, they may have substantially different pathologic effects on the developing fetus. 
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For this reason, it is important to conduct investigations into any emerging vector-borne 
threat to understand both the short- and long-term impacts of maternal infections.
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TABLE 1
Maternal Characteristics
West Nile virusillness
N = 28
Uninfected women
N = 25 p-Value
Maternal age (mean ± SD) 29.4 ± 6.0 31.8 ± 4.3 0.109
Pre-pregnancy BMI (mean ± SD) 25.2 ± 4.0 26.3 ± 7.0 0.480
Planned pregnancy 17 24 0.002
Ethnicity
 White 24 24 0.399
 Hispanic 3 1
 Native American 1 0
Education
 Graduate/professional 2 8 0.005
 College 15 17
 High school 12 0
Household incomea
 >$60,000 7 16 0.002
 $40,000–$60,000 4 2
 $9000–$40,000 9 3
 <$9,000 4 0
Tobacco use 7 1 0.053
Alcohol use 5 2 0.256
Drug use 2 0 0.492
Maternal birth defects 1 (pyloric stenosis) 0 1.000
Maternal family history of birth defectsb 1 2 0.597
Paternal family history of birth defectsc 3 3 1.000
a
Four in each group declined to report.
bOne of WNV group unsure.
c
Three of WNV group unsure.
BMI, body mass index.
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TABLE 2
Pregnancy and Delivery Characteristics
West Nile virus illness
N = 28
Uninfected women
N = 25 p-Value
Gravidity, median (range) 2 (1–6) 2 (1–4) 0.339
Parity median (range) 1 (0–4) 1 (0–2) 0.734
Pre-existing maternal illness
 Epilepsy 1 0 1.000
Pre-existing pregnancy complications
 Prior spontaneous abortion 8 8 1.000
 Prior preterm birth 3 3 1.000
 Prior stillbirth 2 1 1.000
 Prior fetal growth restriction 1 0 1.000
 Prior preeclampsia /eclampsia 1 0 1.000
 Prior children with birth defects 1 (Down syndrome) 0 1.000
Current pregnancy
Had prenatal care 28 25 1.000
Folic acid supplementa 24 23 1.000
Other medications used by indicationb
 Cold/upper respiratory infection 5 2 0.426
 Urinary tract infection 4 1 0.355
 Hypothyroidism 1 2 0.597
 Nausea and vomiting 4 3 1.000
 Fever 3 0 0.238
 Sleep 3 0 0.238
 Mood disorders 2 1 1.000
 Other 3 2 1.000
 Total medications used 25 11 0.001
Pregnancy complications
 Gestational hypertension / pre-eclampsia 1 3 0.333
 Febrile illness 15 0 < 0.001
 Vaginal bleeding over 20 weeks 3 0 0.238
 Placental abruption 2 0 0.492
 Placenta previa 1 0 1.000
Maternal infection (other than WNV)
 Cold or flu 4 2 0.672
 Urinary tract infection 4 0 0.113
 Recurrent Herpes 1 2 0.597
 Chlamydia 1 0 1.000
Intrapartum complications
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West Nile virus illness
N = 28
Uninfected women
N = 25 p-Value
Non-reassuring fetal heart tracing 1 0 1.000
Primary cesarean delivery 5 6 0.582
Group B streptococcus colonization 3 4 0.694
Chorioamnionitis 1 0 1.000
a
Four and two missing entries for WNV and uninfected groups, respectively.
b
Medication use in WNV group: acetaminophen, bupropion, hydroxyzine, diphenhydramine, zolpidem, morphine, pantoprazole, azithromycin, 
methylprednisolone, ondansetron, levothyroxine, nitrofurantoin, oseltamivir; medication use in control group: bupropion, levothyroxine, 
enoxaparin, ondansetron, promethazine, acyclovir.
WNV, West Nile virus.
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TABLE 3
Newborn Characteristics
West Nile virus illness
N = 28
Uninfected women
N = 25 p-Value
Presence of umbilical cord blood WNV antibodya
 IgM negative 28 -
 IgG negative - 25
Gestational age at birth, weeks (mean ± SD) 38.6 ± 1.9 38.6 ± 1.1 0.924
Preterm birth 1 0 1.000
Live birth 28 25 1.000
Neonatal death 1 0 1.000
APGARb median (range)
 1 min 8 (3 – 9) 9 (4–9) 0.377
 5 min 9 (8 –10) 9 (7–9) 0.472
Birth weight,b gm (mean ± SD) 3384 ± 374 3501 (± 515) 0.365
Birth length, cm (mean ± SD) 50.5 ± 3.1 50.1 ± 2.4 0.620
Birth head circumference, cm (mean ± SD) 34.3 ± 1.2 34.4 ± 2.0 0.982
Small for gestational ageb 0 0 1.000
Respiratory distress 2 2 1.000
Signs of infection at birthc 0 1 0.481
Hearing test passedd 26 23 1.000
Birth defects-majore 1 (pyloric stenosis) 0 0.481
Birth defects-minor 1 (umbilical hernia) 1 (patent foramen ovale) 1.000
aNewborns from WNV illness mothers not tested for IgG; newborns from uninfected mothers not tested for IgM.
bA preterm birth with neonatal death not included; two missing WNV group birth weight entries.
c
Includes sepsis, pneumonia, seizures, skin rash, thrombocytopenia, cataracts.
d
Two missing entries in each group; one in the WNV illness group because of neonatal death.
e
The mother of the child with pyloric stenosis also had hypertrophic pyloric stenosis.
IgG, immunoglobulin G; IgM, immunoglobulin M; WNV, West Nile virus.
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TABLE 4
Bayley-III Developmental Assessment – Children of Mothers with West Nile Virus Illness
Domain Composite Score N Mean SD Range
Cognitive 17 112.4 19.6 80–145
Language 17 110.9 19.3 79–153
Motor 16 116.3 18.7 85–154
Social-Emotional 15 111.0 22.9 60–145
Adaptive Behavior 14 106.7 13.3 80–127
Not all children were tested, and not all were tested in all domains. The reference mean ± SD of the Bayley-III for Domain Composite Scores is 
100 ± 15.
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